Krazati (adagrasib tablets - Mirati Therapeutics) — Cigna

Initial criteria

• Patient is age ≥ 18 years
• Patient has KRAS G12C mutation-positive disease
• Patient meets ONE of the following (i or ii): i) Patient meets BOTH of the following (a and b): a) Patient has locally advanced or metastatic disease; AND b) Patient has been previously treated with at least one systemic regimen; OR ii) Patient has recurrent disease after resection

Approval duration

1 year